Dr Seth Baum interviews Dr Mikhail Kosiborod about clinical trial data surrounding the possible mechanisms of action of SLGT2 inhibitors for heart failure, as well as the cardio-renal connection.
Dr Peter Jones from Houston Methodist Hospital discusses cardiovascular disease and lipids, topics in which he is speaking about during Consultant360's Cardiometabolic Risk Summit this year.
Dr James Januzzi from Massachusetts General Hospital discusses the new consensus statement on heart failure, biomarker testing for diagnosing heart failure, and potential future treatments.
<p>Dr Thomas Seck from Boehringer Ingelheim Pharmaceuticals discusses the EMPERIAL trials, which aim to expand the use of empagliflozin for heart failure.</p>
Dr Seth Baum, president of the American Society for Preventive Cardiology, welcomes you to our new podcast series and leaves clinicians with a tip for gaining access to heart failure medication.
Low physical activity levels lead to obesity and other comorbidities. On the other end of the spectrum, too much exercise may not be good for the heart either, according to a recent study. The lead author...
Thomas Seck, MD, from Boehringer Ingelheim, spoke with us about the results of the landmark EMPA-REG OUTCOME trial and what they mean for the treatment of diabetes and cardiovascular disease.
<p>Dr Kevin Maki, from Midwest Biomedical Research, speaks to us about his latest review about the effect of omega3 supplementation on cardiometabolic health.</p>
